×
Radiopharm Theranostics - EBITDA 1970-1969 | RADX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Radiopharm Theranostics - ebitda from 1970 to 1969. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
View More
Radiopharm Theranostics - EBITDA 1970-1969 | RADX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Radiopharm Theranostics - ebitda from 1970 to 1969. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$237.5B
Amgen (AMGN)
$162B
Gilead Sciences (GILD)
$142.8B
Vertex Pharmaceuticals (VRTX)
$120.5B
Bristol Myers Squibb (BMY)
$93.6B
CSL (CSLLY)
$84.5B
GSK (GSK)
$79.6B
Regeneron Pharmaceuticals (REGN)
$59.9B
Alnylam Pharmaceuticals (ALNY)
$44.3B
Argenex SE (ARGX)
$36.7B
BioNTech SE (BNTX)
$26.5B
Royalty Pharma (RPRX)
$20.9B
Insmed (INSM)
$20B
Biogen (BIIB)
$18.6B
Illumina (ILMN)
$16.9B
Incyte (INCY)
$15B
Genmab (GNMSF)
$14.7B
Genmab (GMAB)
$14.3B
Moderna (MRNA)
$12.4B
BioMarin Pharmaceutical (BMRN)
$11.3B
QIAGEN (QGEN)
$11.2B
Swedish Orphan Biovitrum (BIOVF)
$10.6B
Ascendis Pharma (ASND)
$10.2B
Exelixis (EXEL)
$9.9B
Bio-Techne Corp (TECH)
$9B
Verona Pharma American Depositary Share (VRNA)
$9B
Exact Sciences (EXAS)
$8.8B
Blueprint Medicines (BPMC)
$8.3B
Roivant Sciences (ROIV)
$7.7B
Legend Biotech (LEGN)
$7.4B